Trophoblast Stem Cell Medium for Authentic Placental Models
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The limited accessibility of human embryos and placental samples, along with the genetic diversity constraints of existing cell lines, hampers the development of reliable in vitro models for trophoblast research, particularly for studying pregnancy-related pathologies such as preeclampsia and placenta accreta.
Innovation Solution
A chemically defined cell culture medium comprising a sphingosine 1-phosphate receptor agonist, an activin/nodal inhibitor, and growth factors is used to differentiate human embryonic stem cells into cytotrophoblasts and trophoblast stem cells, enabling the derivation of two distinct stem cell populations—hPSC-TSCDX2 and hPSC-TS—under controlled conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If human embryos and placental samples are used to derive trophoblast cells, then the cells exhibit authentic trophoblast characteristics, but accessibility and sample availability are severely limited
Solution Approach 1:
The patent creates in vitro copies of trophoblast cells by differentiating human pluripotent stem cells into trophoblast stem cells that replicate the molecular and functional characteristics of primary trophoblast cells. This copying approach allows unlimited access to authentic trophoblast models without needing actual embryonic or placental samples, resolving the contradiction between cell authenticity and sample accessibility
Solution Approach 2:
The patent performs preliminary differentiation of human pluripotent stem cells into trophoblast stem cells under controlled conditions before they are needed for research. This preliminary action creates a ready supply of authentic trophoblast cells that can be accessed on demand, eliminating the need to obtain scarce embryonic or placental samples at the time of experimentation
2Ease of manufacture
If existing trophoblast cell lines are used, then accessibility is improved, but genetic diversity is constrained
Solution Approach 1:
The patent uses human pluripotent stem cells as a universal starting material that can be differentiated into trophoblast cells with diverse genetic backgrounds. This universal approach allows researchers to access cell lines with specific genetic characteristics by selecting appropriate donor cells, thereby achieving both accessibility and genetic diversity simultaneously
Solution Approach 2:
The patent changes the parameter of genetic diversity by deriving trophoblast stem cells from human pluripotent stem cells with different genetic backgrounds. This parameter change allows the creation of multiple cell lines with varied genetic characteristics while maintaining standardized culture conditions, thus improving both accessibility and adaptability
3Reliability
If primary placental samples are cultured, then authentic trophoblast cells are obtained, but cell heterogeneity and contamination with other cell types increase
Solution Approach 1:
The patent segments the differentiation process into distinct stages, first generating trophoblast stem cells with specific molecular markers, then optionally differentiating them into specialized trophoblast subtypes. This segmented approach ensures each stage produces a homogeneous population with defined characteristics, avoiding the heterogeneity problem of primary samples while maintaining authenticity
Solution Approach 2:
The patent employs feedback mechanisms by monitoring specific molecular markers (such as CDX2, GATA3, and other trophoblast-specific markers) during differentiation to ensure homogeneous trophoblast cell populations. This feedback control allows real-time adjustment of differentiation conditions to maintain population homogeneity while preserving trophoblast authenticity
Data Source
AI summary
The present disclosure provides compositions and methods related to the derivation of trophoblast stem cells. In particular, the present disclosure provides novel formulations and methods for deriving and maintaining trophoblast stem cells from human pluripotent stem cells, which can be used for basic research purposes as well as for developing treatments for pregnancy-associated pathologies such as preeclampsia, recurrent loss of pregnancy, placenta accreta, and intrauterine growth restriction.